转移性结直肠癌早期死亡临床计算器:基于ARCAD数据库28项临床试验患者分析
该研究 pooled 了ARCAD数据库中28项随机III期试验的22,654例转移性结直肠癌患者数据,构建30、60、90天死亡的多变量logistic回归模型并开发90天死亡列线图,内部(C指数0.77)和外部验证均显示良好区分度与校准度;30天死亡率1.4%、60天3.4%、90天5.5%。
要点
- 30天死亡率1.4%,60天3.4%,90天5.5%。
- 高龄、低BMI、较差体能状态、转移部位增多、BRAF突变及多项实验室指标与早期死亡风险升高相关。
- 90天死亡列线图内部C指数0.77,外部验证预测准确。
核心结论
- 已开发并验证一个临床列线图,可量化转移性结直肠癌初始治疗期间个体患者的早期死亡风险。
研究设计与样本
- 汇总ARCAD数据库中28项随机III期试验的22,654例患者数据。
- 构建30、60、90天死亡的多变量logistic回归模型,纳入临床和统计学显著的患者及疾病因素与交互项。
- 开发90天死亡列线图,采用bootstrapping法内部验证,并从每项试验随机抽取10%样本进行外部验证。
- 采用时间依赖Cox比例风险模型分析早期进展对90天生存可能性的影响。
主要发现
- 死亡率30天为1.4%,60天为3.4%,90天为5.5%。
- 基线因素中,高龄、较低体重指数、较差体能状态、转移部位数量增加、BRAF突变状态及多项实验室参数与早期死亡可能性增加相关。
- 90天死亡多变量模型显示强内部区分度(C指数0.77),各风险组校准良好,外部验证集总体及患者亚组预测均准确。
临床怎么用
- 该工具可用于未来临床试验的患者 eligibility 评估或风险分层。
- 该工具可识别在治疗期间及治疗后需要更积极或更保守治疗以及额外支持措施的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled. Multivariable logistic regression models for 30-, 60-, and 90-day mortality were constructed, including clinically and statistically significant patient and disease factors and interaction terms. A calculator (nomogram) for 90-day mortality was developed and validated internally using bootstrapping methods and externally using a 10% random holdout sample from each trial. The impact of early progression on the likelihood of survival to 90 days was examined with time-dependent Cox proportional hazards models. Results Mortality rates were 1.4% at 30 days, 3.4% at 60 days, and 5.5% at 90 days. Among baseline factors, advanced age, lower body mass index, poorer performance status, increased number of metastatic sites, BRAF mutant status, and several laboratory parameters were associated with increased likelihood of early mortality. A multivariable model for 90-day mortality showed strong internal discrimination (C-index, 0.77) and good calibration across risk groups as well as accurate predictions in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectal cancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.
引用
- Renfro LA, Goldberg RM, Grothey A, et al. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. J Clin Oncol. 2017. PMID: 28414610. doi:10.1200/JCO.2016.71.5771
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。